Searchable abstracts of presentations at key conferences in endocrinology

ea0092ps1-09-01 | Thyroid Cancer | ETA2023

Thyroid cancer and endocrine disruptive chemicals: a case-control study on per-fluoroalkyl substances (PFAS)

Lugaresi Marina , Pirard Catherine , Moneta Claudia , Dufour Patrice , Fugazzola Laura , Charlier Corinne , Cirello Valentina

Objectives: The worldwide incidence of thyroid cancer (TC) is increasing at an alarming rate in the last decades and environmental pollution has been suggested to be involved in this rise. Some environmental pollutants, namely endocrine disruptive chemicals (EDCs), have been linked to endocrine system disruption, including thyroid dysfunction, and increased risk of cancer. Among EDCs, per- and polyfluoroalkyl substances (PFAS) are widely used in many industrial and consumer pr...

ea0092ps1-09-06 | Thyroid Cancer | ETA2023

Targeting the DNA damage response kinase CHK1 in TP53-mutated thyroid cancer: in vitro studies

Manzo Alessandro , Cirello Valentina , Stellaria Grassi Elisa , Colombo Carla , Fugazzola Laura , Persani Luca

Objectives: Differentiated TCs are generally sensitive to first line treatments and tyrosine kinase inhibitors (TKIs). However, part of them along with undifferentiated TC, namely Anaplastic (ATC) and Poorly Differentiated (PDTC), are aggressive and show refractoriness to tyrosine-kinase inhibitors (TKIs) treatments. A correlation between resistance to TKIs and inactivating TP53 mutations was proven in TC by our group, consistent with data obtained in other tumors. To...

ea0092ps3-29-07 | Treatment 2 | ETA2023

Hypocalcemia occurrence in patients with advanced thyroid cancer during tyrosine-kinase inhibitor treatment

Moneta Claudia , Trevisan Matteo , Colombo Carla , Ceruti Daniele , Giancola Noemi , Fugazzola Laura , De Leo Simone

Background: Several adverse events are recorded during treatment with tyrosine-kinase inhibitors (TKIs). Hypocalcemia was reported during phase III clinical trials with both Lenvatinib and Vandetanib, but scanty data are available in a real-life setting. Aim of our study was to evaluate hypocalcemia occurrence and its characteristics in a cohort of patients treated with these drugs for advanced thyroid cancer. Moreover, in patients treated with Lenvatinib, we examined a possib...

ea0081p217 | Thyroid | ECE2022

A combining pre-surgical thyroid risk score (TRS) for nodules with indeterminate cytology

Colombo Carla , Vannucchi Guia , Muzza Marina , Pogliaghi Gabriele , Palazzo Sonia , Dionigi Gianlorenzo , Persani Luca , Gazzano Giacomo , Fugazzola Laura

Background: Cytology is the gold standard method for the differential diagnosis of thyroid nodules, though 25−30% of them are classified as indeterminate and, in some cases, surgery is required for a definitive diagnosis. Aim: In order to reduce unnecessary thyroid surgeries, we set up a ‘thyroid risk score’ (TRS) to increase the diagnostic accuracy in a large series of patients with indeterminate cytology and to apply it to a validation ...

ea0049ep1432 | Thyroid (non-cancer) | ECE2017

Expression analyses of HABP2 in neoplastic and normal thyroid tissues: could this gene play a role in the pathogenesis of familial non medullary thyroid cancer?

Muzza Marina , Colombo Carla , Proverbio Maria Carla , Ercoli Giulia , Perrino Michela , Cirello Valentina , Vicentini Leonardo , Ferrero Stefano , Fugazzola Laura

Recently, the G534E variant of the HABP2 gene was reported as the underlying genetic defect in large kindred with non-syndromic familial non medullary thyroid cancer (FNMTC), but these data were not confirmed in additional cohorts. Consistently, we found in our wide series of FNMTC that the HABP2G534E variant is frequent, but does not segregate with the disease. Nevertheless, a possible role for this gene in the pathogenesis of FNMTC cannot definitely ruled out also because co...

ea0044oc3.1 | Thyroid and Neoplasia | SFEBES2016

Frequent Occurrence of DUOX2 and DUOXA2 Mutations in Cases with Borderline Bloodspot Screening TSH who Develop ‘True’ Congenital Hypothyroidism

Peters Catherine , Nicholas Adeline K , Lyons Greta , Langham Shirley , Serra Eva , Schoenmakers Erik , Muzza Marina , Fugazzola Laura , Schoenmakers Nadia

The UK newborn screening programme for congenital hypothyroidism (CH) facilitates prevention of neurodevelopmental delay in CH by enabling prompt diagnosis and treatment. Although the UK Newborn Screening Programme Centre (UKNSPC) defines a borderline bloodspot screening TSH (bsTSH) concentration as 10–20 mU/l, the lower cutoff used at Great Ormond Street Hospital (6 mU/l), enables diagnosis of true and transient CH in cases missed using UKNSPC criteria. We hypothesised t...

ea0029p1797 | Thyroid cancer | ICEECE2012

Papillary thyroid carcinoma with high percentage of BRAFV600E alleles have a higher recurrence rate

Guerra A. , Fugazzola L. , Marotta V. , Cirillo M. , Di Stasi V. , Volpe A. , Murino A. , Di Stasi M. , Vitale M.

Context: Although unexplained conflicting results are present in the literature, most of studies report the association of BRAFV600E in papillary thyroid carcinoma (PTC) with a more advanced disease and with a worst prognosis. We recently demonstrated that in most of the cases PTC consists of a mixture of tumour cells with wild-type and mutant BRAF. Hence, we examined the association of percentage of BRAFV600E alleles with clinicopathologic parameters at diagnosis and disease ...

ea0020htc4 | Hot topics: Clinical | ECE2009

ESE Young Investigator Award

Cordella Daniela , Muzza Marina , Bombled Johny , Bressac-de Paillerets Brigitte , Beck-Peccoz Paolo , Schlumberger Martin , Persani Luca , Fugazzola Laura

Germline activating mutations of the RET proto-oncogene are associated with inherited medullary thyroid cancer (MTC) and can be also detected in about 10% of apparently sporadic MTC cases. In the present study, 4 novel RET mutations, located in the extracellular domain (A510V, E511K and C531R) and in the intracellular juxtamembrane region (L666N), all identified by the genetic screening on sporadic MTC cases, are firstly reported and functionally characterized. RET Plasmids ca...

ea0016oc2.5 | Thyroid | ECE2008

Fetal cell microchimerism in papillary thyroid cancer: a possible role in tumor damage and tissue repair

Cirello Valentina , Recalcati Maria Paola , Muzza Marina , Rossi Stefania , Perrino Michela , Beck-Peccoz Paolo , Finelli Palma , Fugazzola Laura

Fetal cells enter the maternal circulation during pregnancy and can persist in the maternal blood or tissues for decades, creating a physiological microchimerism. Since papillary thyroid cancer (PTC) is more frequent in female gender and it is the second more frequent tumor during pregnancy, the role of persisting microchimeric cells has been investigated. Tumour tissue specimens were obtained from 62 women with PTC, 41 of whom had at least one male child before the diagnosis ...

ea0016p698 | Thyroid | ECE2008

Absence of sonic hedgehog mutations in a large cohort of children with thyroid dysgenesis

Muzza Marina , de Filippis Tiziana , Gastaldi Roberto , Weber Giovanna , Lorini Renata , Beck-Peccoz Paolo , Persani Luca , Fugazzola Laura

Thyroid dysgenesis accounts for 75% of all cases of congenital hypothyroidism (CH), and includes thyroid agenesis or hemiagenesis, thyroid hypoplasia, and thyroid ectopy. Thyroid transcription factors TTF-1, TTF-2 and Pax-8, which are involved in the development of the thyroid gland and its normal migration, have been indicated as the best candidate genes but have been found to be mutated in a minority of cases. Sonic Hedgehog (Shh) protein is involved in several key events du...